Observational findings link innate immune gene variants to earlier breast cancer onset in BRCA1 carriers, suggesting new risk prediction approaches.
These findings highlight a potential role for innate immune pathways as modifiers of BRCA1 penetrance and support the development of more refined, personalised risk prediction models.
No takes yet. Share an insight, caveat, or question.
Shemesh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: